Endo International PLC (NASDAQ:ENDP) (TSE:ENL) – Piper Jaffray Companies increased their FY2018 earnings estimates for Endo International in a report issued on Thursday, November 8th. Piper Jaffray Companies analyst D. Amsellem now forecasts that the company will post earnings of $2.73 per share for the year, up from their previous estimate of $2.55. Piper Jaffray Companies also issued estimates for Endo International’s Q1 2019 earnings at $0.51 EPS and Q2 2019 earnings at $0.63 EPS.
Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Thursday, November 8th. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.12. The firm had revenue of $745.00 million for the quarter, compared to the consensus estimate of $694.93 million. Endo International had a positive return on equity of 237.45% and a negative net margin of 34.72%. The firm’s revenue for the quarter was down 5.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.91 EPS.
Several other analysts also recently weighed in on the company. Royal Bank of Canada raised Endo International from a “sector perform” rating to an “outperform” rating and set a $26.00 target price on the stock in a research note on Monday, August 13th. Zacks Investment Research raised Endo International from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Monday, September 24th. Goldman Sachs Group raised Endo International from a “sell” rating to a “neutral” rating and lifted their target price for the company from $14.00 to $15.00 in a research note on Tuesday, September 11th. TheStreet raised Endo International from a “d” rating to a “c-” rating in a research note on Monday, August 20th. Finally, BidaskClub downgraded Endo International from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 8th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Endo International currently has an average rating of “Hold” and an average price target of $14.97.
Shares of Endo International stock opened at $13.19 on Friday. The firm has a market cap of $3.84 billion, a price-to-earnings ratio of 3.43, a price-to-earnings-growth ratio of 1.65 and a beta of 0.65. Endo International has a 1-year low of $5.27 and a 1-year high of $18.50.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Teachers Retirement System of The State of Kentucky grew its holdings in shares of Endo International by 85.5% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 61,600 shares of the company’s stock worth $1,037,000 after acquiring an additional 28,400 shares during the last quarter. Commonwealth Bank of Australia grew its holdings in shares of Endo International by 450.5% in the 3rd quarter. Commonwealth Bank of Australia now owns 87,250 shares of the company’s stock worth $1,465,000 after acquiring an additional 71,400 shares during the last quarter. Toronto Dominion Bank acquired a new position in shares of Endo International in the 3rd quarter worth $532,000. O Shaughnessy Asset Management LLC acquired a new position in shares of Endo International in the 3rd quarter worth $1,046,000. Finally, Meeder Asset Management Inc. grew its holdings in shares of Endo International by 23,503.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 66,799 shares of the company’s stock worth $1,124,000 after acquiring an additional 66,516 shares during the last quarter. Institutional investors and hedge funds own 98.43% of the company’s stock.
In related news, Director Roger H. Kimmel sold 26,074 shares of Endo International stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $15.90, for a total value of $414,576.60. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.80% of the company’s stock.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Further Reading: Do You Need a Fiduciary?
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.